Kala Pharmaceuticals Inc. (NASDAQ:KALA) said FDA approved Inveltys (KPI-121 1%) to treat post-operative inflammation and pain following ocular surgery. According to the company, Inveltys is the first twice-daily ocular corticosteroid approved for the indication; all other ocular steroids are approved for dosing four times a day.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,